



PRESS RELEASE

Celeros equipment selected by Sanofi Pasteur for new Vaccine Production Facility

Celeros to Provide Advanced Technology for Plant Expansion

FOXBORO, MA U.S., Dec. 15 -- Celeros Inc., specialty equipment manufacturer, announced today that it was selected by Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, as a supplier of advanced centrifuge separations equipment for a new vaccine facility in Marcy l'Etoile, France.

Celeros was selected based on their breakthrough technologies and expertise in solid liquid separations. The equipment is recognized as a new generation centrifuge system of industrial interest. Through a tight collaboration with Sanofi Pasteur this new equipment should be implemented in one of Sanofi Pasteur cutting-edge vaccine production facilities in Marcy l'Etoile.

The new automated centrifuges from Celeros, once qualified, will enable Sanofi Pasteur to achieve a closed system process approach and a high level of automation with improved productivity.

"Our respective organizations have a similar focus on process improvements to drive quality and productivity," said Greg Cybulski, Director of Sales and Marketing for Celeros. "As with all our partners, we are pleased to be working closely with Sanofi Pasteur to help them achieve their goals."

Among the new equipment purchased by Sanofi Pasteur are the latest versions, mid-sized, Celeros Automated Piston Discharge (APD), high performance centrifuges, capable of precise, low moisture solids recovery, superior to disk machines.

About Sanofi Pasteur

Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, provided more than 1.6 billion doses of vaccine in 2009, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: www.sanofipasteur.com or www.sanofipasteur.us



About Celeros Inc.

Celeros Inc creates business advantages for biotech and pharmaceutical organizations by delivering practical and sustainable innovation to enable significant advancements in process yield and cost control. Pioneering patented Automated Discharge technology for demanding Biotech and pharmaceutical separation applications, Celeros' innovations provide an enduring platform for customer success. Celeros is driving process improvement and operational excellence for customers worldwide. For more information visit www.celerosinc.com .

Contact:

Celeros Inc:

Worldwide Sales

Greg Cybulski

T. 508-698-3080 x109

greg.cybulski@celerosinc.com

SOURCE: Celeros Inc.